Investing.com - Tscan Therapeutics (NASDAQ: TCRX) reported third quarter EPS of $-0.24, $0.21 better than the analyst estimate of $-0.45. Revenue for the quarter came in at $3.89M versus the consensus estimate of $4.45M.
Tscan Therapeutics's stock price closed at $4.31. It is up 109.22% in the last 3 months and up 56.16% in the last 12 months.
Tscan Therapeutics saw 3 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Tscan Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Tscan Therapeutics's Financial Health score is "fair performance".
Check out Tscan Therapeutics's recent earnings performance, and Tscan Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar